FENC Share Price | Fennec Pharmaceuticals, Inc. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Dec 2025)

FII

48.70%

Held by 161 FIIs

DII

51.3%

Held by 2 DIIs

Promoter

0.00%

Compare Fennec Pharmaceuticals, Inc. with Similar Stocks

Knight Therapeutics, Inc.Ayr Wellness, Inc.Cybin, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate 5.44% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -11.26

Negative results in Jun 25

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 279 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.04

Return on Equity

-23.17%

Price to Book

5.74

Revenue and Profits:

Net Sales:

19 Million

(Quarterly Results - Dec 2025)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-17.79%

6 Months

-24.19%

1 Year

3.74%

2 Years

-29.49%

3 Years

-19.22%

4 Years

18.27%

5 Years

19.06%

Fennec Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

123.02%

EBIT Growth (5y)

11.64%

EBIT to Interest (avg)

-11.26

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.78

Sales to Capital Employed (avg)

2.07

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

56.67%

ROCE (avg)

ROE (avg)

18.98%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-57.05

EV to EBIT

-53.96

EV to EBITDA

-53.96

EV to Capital Employed

-30.29

EV to Sales

6.48

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 161 Foreign Institutions (48.7%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 72.97% vs -16.54% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -213.04% vs 37.84% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19.20",
          "val2": "11.10",
          "chgp": "72.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.20",
          "val2": "-1.30",
          "chgp": "-223.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "1.40",
          "chgp": "-64.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.80",
          "val2": "-0.10",
          "chgp": "-2,700.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.20",
          "val2": "-2.30",
          "chgp": "-213.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-218.90%",
          "val2": "-117.90%",
          "chgp": "-10.10%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -4.15% vs 126.83% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -2,166.67% vs 97.24% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "62.40",
          "val2": "65.10",
          "chgp": "-4.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.80",
          "val2": "3.50",
          "chgp": "-351.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.00",
          "val2": "5.70",
          "chgp": "-47.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.80",
          "val2": "-0.10",
          "chgp": "-2,700.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.60",
          "val2": "-0.60",
          "chgp": "-2,166.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-140.70%",
          "val2": "54.00%",
          "chgp": "-19.47%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

19.20

11.10

72.97%

Operating Profit (PBDIT) excl Other Income

-4.20

-1.30

-223.08%

Interest

0.50

1.40

-64.29%

Exceptional Items

-2.80

-0.10

-2,700.00%

Consolidate Net Profit

-7.20

-2.30

-213.04%

Operating Profit Margin (Excl OI)

-218.90%

-117.90%

-10.10%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 72.97% vs -16.54% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -213.04% vs 37.84% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

62.40

65.10

-4.15%

Operating Profit (PBDIT) excl Other Income

-8.80

3.50

-351.43%

Interest

3.00

5.70

-47.37%

Exceptional Items

-2.80

-0.10

-2,700.00%

Consolidate Net Profit

-13.60

-0.60

-2,166.67%

Operating Profit Margin (Excl OI)

-140.70%

54.00%

-19.47%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -4.15% vs 126.83% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -2,166.67% vs 97.24% in Dec 2024

All Annual Results

Company CV

About Fennec Pharmaceuticals, Inc.

Fennec Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

Company Coordinates

Company Details

68 Tw Alexander Dr, PO Box 13628 DURHAM NC : 27709-3628

Tel: 1 919 6364530

http://fennecpharma.com

Registrar Details